Introduction
The 20th anniversary of the first umbilical cord blood transplant (UCBT), performed in a 6-year-old boy with Fanconi anemia from his human leukocyte antigen (HLA)-matched sibling, was celebrated in the United States and France in 2008. The patient, now 26 years old, durably engrafted and well, attended the session and spoke eloquently about the decision his parents made to allow him to undergo this first-in-man clinical experiment. Despite the ultimate success of this transplant, at the time, it was considered highly unlikely that cord blood would emerge as a standard source of stem and progenitor cells for hematopoietic stem cell transplantation (HSCT). Yet, today, cord blood is donated and banked for unrelated-donor transplantation on a routine basis. There are more than 400 000 units banked in inventory in more than 100 unrelated-donor banks, facilitating more than 14 000 unrelated-donor cord blood transplants worldwide.
Background and history
Since the first allogeneic transplant for a child with severe combined immunodeficiency syndrome in 1968, thousands of patients have been cured of lifethreatening malignant and nonmalignant hematologic and genetic disorders, establishing the field of marrow transplantation. Over the years, the National Marrow Donor Program (NMDP) in the United States and other international registries have recruited, typed and maintained databases of more than 13 million volunteer unrelated adult donors. Despite this large number of donors, approximately 50-70% of the patients in need of a transplant are still unable to find a suitable adult donor in a timely manner. This problem is more prominent in patients belonging to ethnic and racial minorities who, because of larger HLA diversity and some reluctance to volunteer as adult donors, have an even lower probability of identifying an unrelated adult donor.
Banked umbilical cord blood provides access to transplantation
After the success of the initial related cord blood transplant [1] , approximately 60 others were performed in the matched-sibling setting and results were reported to a volunteer international registry demonstrating that cord blood contained sufficient numbers of hematopoietic stem and progenitor cells to reconstitute a pediatric patient and also that there was a lower incidence of acute and chronic graft-versus-host disease (GvHD) when cord blood, as compared with bone marrow, was used as the source of donor cells [2] . This led to the hypothesis that cord blood could be banked and used as a source of unrelated donor cells, possibly without full HLA matching [3] . In 1992, Dr Pablo Rubinstein established a pilot unrelated-donor umbilical cord blood (UCB) bank at the New York Blood Center [4] . In 1993, the first unrelateddonor UCBT was performed with a unit from this bank in a child with refractory leukemia at Duke University Medical Center [5] .
The idea of using cord blood for hematopoietic transplantation arose from interactions among a group of physicians and scientists in the early 1980s. Using blood from nearterm mouse donors, Dr Ted Boyse at Memorial Sloan Kettering Cancer Center demonstrated reconstitution of hematopoiesis in lethally irradiated mice. Concomitantly, Dr Hal Broxmeyer in New York and Indiana performed early experiments characterizing the hematopoietic stem and progenitor cells in human UCB, demonstrating that cord blood-derived hematopoietic progenitor cells (HPC) had higher proliferative capacity and higher replating potential as compared with similar cells in bone marrow, and also that HPC from cord blood could be readily cryopreserved [3, 6] . Furthermore, in-vivo studies in non-obese diabetic (NOD)/severe combined immunedeficient (SCID) repopulating cell assays have shown that the SCID-repopulating cell (SRC) frequency in UCB is three-fold higher than in marrow and six-fold higher than in mobilized peripheral blood, suggesting that UCB contains a higher proportion of primitive HSCs and HPCs [6] .
Unrelated-donor umbilical cord blood transplantation
In 1993, the first unrelated UCBT was performed in a 3-year-old child with refractory T-cell acute lymphoblastic leukemia utilizing four of six matching cord blood units from the New York Blood Center. Although this child engrafted, he later died of interstitial pneumonitis. A second child, also with refractory leukemia, transplanted with four of six matched cord bloods, survived more than 15 years later in remission with full donor chimerism, normal immune function and no evidence of GvHD. Subsequently, the outcomes of the first 25 suc-cessive transplants with unrelated UCB banked at the New York Blood Center, and transplanted at Duke University, were reported in 1996 [5] . Important observations in these patients, which were confirmed in subsequent reports from other centers and transplant registries including the New York Blood Center and the European Cord Blood Registry (Eurocord) [7] [8] [9] , confirmed that banked unrelated-donor cord blood contained sufficient numbers of stem and progenitor cells to reconstitute the marrow of children undergoing myeloablative therapy for leukemias, congenital marrow failure and genetic diseases without full HLA matching between the donor and recipient. These patients experienced a lower incidence and severity of acute and chronic GvHD as compared with that seen with matched unrelated marrow transplants without loss of graft-versus-leukemia (GvL) effects [9] . In these patients, cell dose strongly correlated with clinical outcomes, including time to and probability of engraftment and probability of overall survival (OS) [5] [6] [7] [8] [9] . Engraftment times were observed to be slower than those seen when marrow or mobilized peripheral blood was used as the source of donor stem cells.
Donor-recipient-matching strategies for cord blood transplantation established in the days of these early transplants were much less stringent than those used for adult donors. Low-resolution (antigen level) matching was used at HLA class I A and B loci with high-resolution matching for HLA class II DRB1. Matching at HLA C, DQ or DP was not employed. This approach continues to be used for donor cord blood unit selection, although the question of whether allele level matching at class I, as well as class II or HLA C matching, would improve outcomes currently remains unanswered.
First prospective study: Cord Blood Transplantation
The first prospective, multi-institutional study of cord blood banking and transplantation in the United States was sponsored by the National Heart, Lung, and Blood Institute, which funded a prospective multicenter clinical trial of unrelated cord blood banking and transplantation -the Cord Blood Transplantation (COBLT) study -from 1997 to 2004. As part of this study, three additional unrelated cord blood banks were established. A steering committee of bankers, obstetricians, ethicists and transplanters created common quality standards and standard operating procedures (SOPs) addressing donor recruiting and screening, cord blood collection, processing, testing, cryopreservation, storage and thawing for transplantation [10, 11] . Maternal donors were screened for events in their medical history that would exclude them as donors (e.g., multiple pregnancy, congenital anomalies, prematurity, placental deformity, a firstdegree relative of the baby donor diagnosed with cancer, Update on umbilical cord blood transplantation Kurtzberg 23 prior receipt of a transplant or demonstration of high-risk behaviors likely to increase the chance of infection with blood-borne infectious diseases). SOPs were also established and validated for obtaining donor consent; obtaining medical histories; obtaining blood samples from maternal donors; cord blood collecting, processing, testing, cryopreservation and storage; as well as searching for and releasing cord blood units for transplantation. Twenty-six transplant centers participated in the COBLT study, a prospective clinical trial designed to examine the safety of unrelated cord blood transplantation in infants, children and adults with malignancies; children with congenital immunodeficiency disorders and children with inborn errors of metabolism. Definitions of engraftment, grading of GvHD, toxicity scoring and algorithms for causes of death were developed. The study used common preparative regimens, prophylaxis against GvHD and supportive care measures.
Results of the individual strata of the COBLT study have now been published [12] [13] [14] 15 ] . Overall outcomes in children with malignant and nonmalignant conditions were favorable, with 2-year, event-free survival of 55% in children with high-risk malignancies [15 ] and 78% survival in children with nonmalignant conditions [14] . The cumulative incidence of engraftment by day 42 after transplantation was approximately 80% in all study strata, including adults and children as well as children with malignant diseases, inborn errors of metabolism and immunodeficiency syndromes. Factors adversely affecting engraftment or survival included lower cell doses, pretransplant cytomegalovirus seropositivity in the recipient, non-European ancestry and higher HLA mismatching. In the strata of patients with pediatric malignancies, there was no difference in outcomes between those patients receiving four of six or five of six matched grafts. The number of patients receiving six of six matched grafts was very small, but these patients appeared to have superior survival as compared with those transplanted with HLA-mismatched grafts.
The COBLT study results in a very high-risk group of adults were inferior to those seen in children and in individuals receiving marrow from an unrelated donor. Subsequent studies [13, 16, 17] in adults, reported by single centers or registries, revealed more encouraging results. Most recently, the use of two cord blood units for a single transplant, pioneered in adults by Drs John Wagner and Juliet Barker at the University of Minnesota, has improved rates of both engraftment and survival, increasing the use of cord blood donors in adults around the world [18] . In these pilot studies, the proportion of patients engrafting with their cord blood donor(s) increased to at least 90% and overall 1-year survival increased to 60-80% depending upon patient diagnosis, comorbidities and disease status at the time of transplant.
Interestingly, when two cord blood units are administered, one generally engrafts and the other is rejected. This typically occurs in the first month after transplant. The engrafting unit cannot be predicted by traditional parameters such as cell dose, timing of administration, HLA match or CD34 or CFU dosing. The exact role of the nonengrafting cord blood unit remains unclear but is the subject of current preclinical and clinical studies. To further determine the role of two versus one cord blood units, the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) , a National Institutes of Health (NIH)-sponsored cooperative group for multiinstitutional transplant clinical trials, is currently sponsoring a study in pediatric patients with hematological malignancies asking, in a randomized, prospective phase III clinical trial, whether outcomes are better when one or two cord blood units are used to deliver donor hematopoietic stem cells. This study will help determine whether two cord bloods are better than one.
Retrospective and registry studies
Over the nearly 15 years since the first unrelated-donor cord blood transplantation, more than 14 000 such procedures have been performed at more than 150 centers located throughout the world. Retrospective analyses performed by transplant registries in the United States and Europe supported the conclusions reached in the early studies of UCBT. Efficacy of unrelated cord blood transplantation has been demonstrated in children and adults with hematological malignancies and children with a variety of nonmalignant disorders, including hemoglobinopathies [19] , immunodeficiencies [20, 21] and inborn errors of metabolism [14,22 ,23,24,25 ] . A majority of transplants have been mismatched at one or two HLA loci. Yet, a recent retrospective comparative analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) of unrelated-donor graft sources -cord blood versus marrow -showed a comparable 5-year leukemia-free survival in children with acute leukemia who received allele-matched marrow versus one or two-antigen mismatched cord blood transplants. The analysis suggests that six of six matched cord bloods may yield superior survival, even though the comparison fell short of statistical significance, likely because of the small numbers of patients receiving six of six matched grafts available for this analysis [26 ] . A minimum cell dose threshold of 2.5-3.0 Â 10 7 nucleated cells/kg in the cryopreserved cord blood has been associated with superior clinical outcomes [5,7-9,15 ,22 ] .
Umbilical cord blood transplantation for children with inherited metabolic disorders
Cord blood transplantation has been particularly effective in the treatment of young infants and children with Figure 1 Neurocognitive improvement of 20 consecutive patients with severe phenotype Hurler syndrome transplanted with unrelated donor cord blood at a median of 16 months of age and followed for 5-7 years Adapted from [23] .
certain inborn errors of metabolism, for example, mucopolysaccharidoses such as Hurler syndrome and leukodystrophies such as Krabbe disease [22 ,23,24,25 ] . These diseases are examples of lysosomal and peroxisomal storage diseases, which result from single-gene defects leading to specific enzyme deficiencies. These deficiencies cause defective lysosomal breakdown and accumulation of a toxic substrate, which in turn leads to progressive involvement of brain and other organs and premature death. In these patients, durably engrafted cord blood cells of donor origin provide a form of cellbased enzyme replacement therapy. Donor cells provide continuous, life-long production of the missing or defective enzyme. For example, most patients with untreated severe phenotype Hurler syndrome (MPS I) die between 5 and 10 years of age from progressive cardiac and pulmonary involvement. They also suffer from severe bone abnormalities, corneal clouding, massive hepatosplenomegaly and severe neurocognitive impairment. Engrafted cord blood cells have the ability to cross the blood-brain barrier and have been shown to prevent neurological deterioration and even cause cognitive improvement (Fig. 1) , a beneficial outcome that is not expected with the alternative approach of enzymereplacement therapy [22 ,23,25 ] . Unrelated cord blood transplantation, when performed before the age of approximately 2 years, leads to correction of cardiac, pulmonary, liver and neurologic damage and improves survival. In fact, a recent risk factor analysis of 146 patients from the European Group for Blood and Marrow Transplantation (EBMT) suggests that cord blood could be the preferred stem cell source in this disease [25 ] .
In patients with leukodystrophies, cord blood transplantation has been shown to be maximally effective when performed in patients with presymptomatic or minimally symptomatic disease. In these patients, UCBT can prevent demyelination in the central and, often, the peripheral nervous systems, extending life and improving the overall quality of life for these patients [22 ,24,25 ] . Neurocognitive function is preserved in all newborn patients while varying degrees of motor disability persist. In contrast, symptomatic infants undergoing UCBT fail to gain neurological skills after transplant. UCBT is no longer recommended for symptomatic infants with Krabbe Disease ([24], Fig. 2 ). Successes using UCBT in newborns with infantile forms of Krabbe disease have led to the development of a pilot newborn screening programme in New York State.
A recently published series of 159 consecutively transplanted pediatric patients with inherited metabolic diseases showed that performance status and various characteristics of the infused graft best predicted clinical outcomes [25 ] . Post-thaw content of colony-forming units granulocyte-macrophage (CFU-GM) and CD34 þ cell counts best predicted both engraftment and OS (Fig. 3) . 
Advantages and disadvantages of cord blood transplantation
Cord blood transplantation has several advantages over marrow or peripheral blood stem cell transplantation, the most significant of which is that cord blood transplantation can be performed successfully from an unrelated donor with one or two HLA mismatches. Banked cord blood is readily available, generally within 1-2 weeks. There is minimal donor attrition and easier recruitment of minority donors. Current obstacles to successful use of UCBT include smaller inventories with lower cell doses and lack of sufficient donors to provide five of six or six of six matches for all patients in need. Slower engraftment of neutrophils leads to longer hospitalizations and increased utilization of medical resources.
There are also significant limitations dictated mainly by the kinetics of cord blood engraftment. The majority of single cord blood units do not contain sufficient numbers of nucleated cells to be of benefit for adult patients. Delays in immune reconstitution lead to an increased risk of viral infections, particularly in the first year after transplant.
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Cord blood banking
UCB is the remainder of the newborn infant's blood contained in the placenta after birth. It used to be routinely discarded at birth. Cord blood can be harvested without physical risk to the mother or infant donor from the delivered placenta (ex utero) or during the third stage of labor (in utero). In either case, after sterile preparation, the umbilical vein is punctured with a needle attached to a sterile, closed-system collection bag containing citratephosphate-dextrose or heparin anticoagulant, which is positioned lower than the placenta. Blood flows from the placenta through the cord into the bag by gravity over approximately 5-10 min. Experienced collectors harvest an average of 110 ml of blood, containing approximately 1 Â 10 9 nucleated cells from a single placenta. The cord blood unit is labeled and subsequently shipped to the cord blood bank for processing, testing, cryopreservation and storage [11] .
There are two types of cord blood banks, public and private. In public banks, cord blood units are donated on a volunteer basis after written informed consent by mothers delivering healthy infants at term. There is no cost to donate to a public bank. Private banks, which are for-profit entities, store 'directed donations' collected by obstetricians or midwives from infants born into families who intend to use the cord blood for autologous use or for a biological sibling in need of future transplantation therapy. Although the indications for directed donation are relatively clear (e.g., a biological sibling with a hematological malignancy, hemoglobinopathy, marrow failure, immunodeficiency or inherited metabolic disease), the indications for autologous use are predominantly speculative at this time. It is possible that autologous cord blood could provide a source of stem and progenitor cells for cellular therapies, tissue repair and regeneration in the future, but these therapies are not possible at the present time.
In 2004, after appropriation of $20 000 000 by the US Congress to increase the inventory of cord blood units in US public banks, the Health Resources Services Administration (HRSA) asked the Institute of Medicine (IOM) to perform a study to determine the best way to organize public cord blood banking and distribution to patients undergoing unrelated transplantation, the results of which were published in April 2005 [27] . In brief, the IOM recommended that HRSA should contract with eligible banks to procure approximately 150 000 new, ethnically diverse, high-quality, unrelated-donor cord blood units over the next 5 years. Subsequently, the US Congress passed legislation that established the C.W. 'Bill' Young Stem Cell Transplantation Program, a federally funded programme, which established a network of public cord blood banks [the National Cord Blood Inventory (NCBI)], a single point of access donor registry, separate bone marrow and cord blood coordinating centers and an outcomes database, the Stem Cell Transplant Outcomes Database (SCTOD), all administered through HRSA. Contracts were awarded to nine public cord blood banks, the NMDP and the CIBMTR to administer these programmes. In 2008, a sibling donation programme, providing directed donor banking of cord blood from biological siblings of children with cancer, hemoglobinopathies and other blood disorders treated with allogeneic transplantation at no cost to the family, was launched by HRSA.
Conclusion
Despite limited enthusiasm in its early days, the field of cord blood transplantation is now firmly established. UCB from related and unrelated donors, matched or mismatched at one or two antigens, is now widely regarded as an alternate donor source to matched marrow or peripheral blood for allogeneic transplantation in children as well as adults for a variety of malignant and nonmalignant disorders. This use of cord blood dramatically increases access to transplantation therapy for patients lacking matched-related or unrelated adult donors. Retrospective, registry and single-center reports of UCBT outcomes show comparable results when cord blood or adult cells are used as donors. Yet, despite these successes, cord blood transplantation still faces many challenges. Delayed hematopoietic engraftment and immune reconstitution continue to limit its overall success. Results of UCBT in children with metabolic diseases suggest that cord blood contains cells capable of nonhematopoietic differentiation, suggesting that cord blood may be a viable source of cells for cellular therapies as this field continues to mature [28, 29 ] . For the present, cord blood has established itself as an important source of allogeneic donor cells increasing access to transplantation for many patients in need. Larger inventories, higher-quality units, the development of potency assays and US Food and Drug Administration (FDA) licensure of cord blood should lead to increased usage and improved outcomes after UCBT in the next few years. Applications for cellular therapies, tissue repair and regeneration remain speculative at present, but it is highly likely that cord blood will emerge as a novel source of cells for cellular therapies within the next decade.
